Mesenchymal Stem Cell Therapy for Liver Disease: Full of Chances and Challenges
October 2020
in “
Cell & Bioscience
”
TLDR Mesenchymal stem cell therapy shows promise for liver disease but faces challenges in standardization and approval.
The document discussed mesenchymal stem cell (MSC) therapy as a promising alternative to liver transplantation for end-stage liver disease, which faced limitations due to organ shortages, high costs, and surgical complications. Although some clinical trials confirmed the effectiveness of MSC therapy, it had not been widely promoted or approved due to unresolved issues. These included determining the most suitable types of liver disease for MSC application and standardizing MSC preparation and engraftment. The study reviewed 22 completed and several ongoing clinical trials to address these challenges and explored the mechanisms by which MSCs exert therapeutic effects. It also proposed new approaches to enhance the efficacy of MSC therapy.
